CAS: 10106-41-9; (16α)-17-Hydroxy-16-Methyl-3,20-Dioxopregna-1,4,9(11)-Trien-21-Yl Acetate
该化合物是一种合成的甘蓝素,具有抗炎性和免疫抑制性特性,其特征为:甲状腺结构,包括环球开胃激素,在17和21个位置上用氢氧基修改,在21个位置上用丙烯基体组和乙酸盐组进行调节,在21个位置上形成一种乙酸盐组.该复合物表现出高度的威力和长时间的动作,使其在治疗诸如过敏性,自动免疫素疾病和某些癌症等各种条件方面有效.
- 英文名称(16α)-17-Hydroxy-16-Methyl-3,20-Dioxopregna-1,4,9(11)-Trien-21-Yl Acetate
- 中文名称17-α,21-二羟基-16-α-甲基孕甾-1,4,9(11)-三烯-3,20-二酮21-乙酸酯
- IUPAC名称2-((8S,10S,13S,14S,16R,17R)-17-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,10,12,13,14,15,16,17-decahydro-3H-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl acetate
- 其它别名17,21-Dihydroxy-16-methylpregna-1,4,9(11)-triene-3,20-dione 21-acetate; 21-Acetyloxy-17-hydroxy-16-methylpregna-1,4,9(11)-triene-3,20-dione
- CAS编号10106-41-9
- MFCD编号:MFCD16876083
- EINECS号:233-290-4
- FDA UNII编号:AOW1NH1RMD
- 分子式:C24H30O5分子量:398.49
- 产品CID: 22542
- 同类组份化合物CAS10106-41-9 (acetate)13209-41-1 (free base)
物理性质
MSDS等安全信息
上下游产品
CAS号912-38-9 9β,11β-环氧-17,21... | CAS号1177-87-3 醋酸地塞米松合成工艺路线路线简述
- 37413-91-5 = 10106-41-9 + 4258-83-7 + 14622-51-6 + 14622-47-0
反应条件:1.1 Catalysts: Cupric Chloride Solvents: Tetrahydrofuran; 1 Min,< 3 °C1.2 Solvents: Tetrahydrofuran; 2 Min,< 3 °C1.3 Reagents: Chlorotrimethylsilane1.4 Solvents: Tetrahydrofuran; 23 Min,< 2 °C; 12 Min,< 2 °C1.5 Reagents: Triethylamine1.6 Reagents: Ammonium Chloride Solvents: Water1.7 Reagents: Peracetic Acid Solvents: Dichloromethane; 4 Min,< 4 °C; 19 H,< 4 °C1.8 Reagents: Hydrochloric Acid Solvents: Water
标题:Expedient Synthesis Of 17α,21-Dihydroxy-9β,11β-Epoxy-16α-Methylpregna-1,4-Diene-3,20-Dione 21-Acetate From Prednisolone Utilising A Novel Mattox Rearrangement
作者:Hulcoop,David G.; Shapland,Peter D. P.
参考文献:Steroids 日期:2013 卷标:78(12-13) 页码:1281-1287
海关参考信息
- 2905122000-异丙醇
2905143000-叔丁醇
2905399001-1,3-丙二醇
2905141000-异丁醇
2905142000-仲丁醇 - 💡 提示：海关信息按照顺序优先匹配，如需确认的海关信息，请参考相关资料。
- 详情请参考：📖 海关编码查询和海关进出口税则
专利信息
专利号:EP-1422235-B1
优先权日:2001-07-26
标题 :Stereoselective method of producing 6alpha-fluoropregnanes and intermediaries
发明人：MURILLO GARRIDO JOSE VICENTE; SILVA GUISASOLA LUIS OCTAVIO; MARTIN JUAREZ JORGE
权利人:RAGACTIVES SL
摘要:6 alpha -fluorpregnanes (I), where the dotted line between positions 1 and 2 represents a single or double bond; R1 is OH, OCOR2, X, SO3R3, or an (R7)(R8)(R9)SiO- group, where X is halogen, R2 and R3 are C1-6 alkyl or phenyl optionally substituted by C1-4 alkyl, and R7, R8 and R9, equal or different, are C1-6 alkyl or phenyl optionally substituted by C1-4 alkyl, can be obtained by means of a high stereoselectivity process comprising reacting a 3-(trisubstituted)silyloxy-pregna-3,5-diene (IV) with a fluorinating agent selected among N-fluorosulfonimides and N-fluorosulfonamides. The 6 alpha -fluorpregnanes (I) are intermediates for the synthesis of steroids useful as anti-inflammatory and anti-asthmatic agents.
专利号:US-4530795-A
优先权日:1984-02-27
标 题 :Process for preparation of 16 α-methyl corticoids from Δ16 -steroids
发明人：HUBER JOEL E
权利人:UPJOHN CO
摘要:This invention discloses a general process for the production of corticoids from respective steroid-type compounds having a double bond from C-16 to C-17. The invention provides a viable alternative synthesis of 17α-hydroxy-progesterones and like corticoids.
供应商参考报价(招募中)
品牌试剂参考报价(招募中)
📌 第三方产品分析报告
主要参考文献
1: Murphy C, Nasomyont N, Tian C, Ryan TD, Villa C, Reebals L, Zygmunt A, Rutter MM. From case to caution: hyponatremia in a patient with Duchenne muscular dystrophy on vamorolone and lessons for clinicians. Neuromuscul Disord. 2026 Mar 14;62:106411. doi: 10.1016/j.nmd.2026.106411. Epub ahead of print. 273(3):177. doi: 10.1007/s00415-026-13711-6.
3: Sbrocchi AM, Kinnett K, Lautatzis ME, McMillan HJ, Selby KA, Veerapandiyan A, Weber DR, Apkon S, Bharucha-Goebel DX, Bharill S, Bansal S, Clemens PR, Fiscaletti M, Halloun R, Lam C, Merchant N, McAdam L, Nasomyont N, Nicolau S, Ochoa Molina MF, Phung K, Rutter MM, Scavina M, Surampudi PN, Tamaroff J, Tian C, Ward LM, Wood CL, Wong SC, Ahmet A; OPTIMIZE DMD Consortium. Adrenal Suppression in Duchenne Muscular Dystrophy: Management Strategies Incorporating Novel Steroid Vamorolone. J Endocr Soc. 2025 Nov 27;10(2):bvaf181. doi: 10.1210/jendso/bvaf181.
4: Jazbinšek S, Vrščaj E, Šuput Omladič J, Butenko T, Loboda T, Kotnik P, Osredkar D. Endocrine and metabolic complications in a national cohort of Slovene children and adolescents with Duchenne muscular dystrophy: real-world criteria for transition to vamorolone therapy. Front Endocrinol (Lausanne). 2025 Dec 5;16:1697907. doi: 10.3389/fendo.2025.1697907.
合成参考文献
摘要:Kleemann A., Kutscher B., Reichert D., Bossart M., Pharmaceutical Substances, Thieme [Online], Stuttgart, (2025).
📝 需求与反馈
尽可能描述清楚需求与问题信息
